Preclinical Studies in CAR T Cell Development

T cells that express chimeric antigen receptors (CARs) have shown remarkable efficacy against CD19 expressing hematological tumors1-3. Patients receive autologous T cells that are typically virally transduced to express a CAR that can recognize a specific antigen expressed on the surface of tumor cells and generates large numbers of effective tumor-specific T cells. The value of preclinical models is to establish some evidence for efficacy, uncover potential toxicities, and to study the mechanism of action.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research